Canada’s new law strengthens drug regulatory powers but is vague on mandatory trial registrationBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g6620 (Published 03 November 2014) Cite this as: BMJ 2014;349:g6620
- Owen Dyer
Canada’s parliament has passed a bill enabling health ministers to compel the recall of unsafe drugs and demand labelling changes, steps that previously required lengthy negotiations with manufacturers.
Bill C-17, which has passed its final reading in the Senate and now awaits only royal assent, brings Canada’s historically weak regulatory powers into line with those in other jurisdictions in developed countries. It also empowers the health minister to disclose confidential business information in explaining decisions and to order companies to conduct post-marketing studies, whose results the national health department, Health Canada, may share with provincial and aboriginal governments.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial